Phase 1/2 Study of RTX-240 Monotherapy and in Combination With Pembrolizumab

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; RTX 240 (Primary)
Indications Acute myeloid leukaemia; Anal cancer; Colorectal cancer; Gastrointestinal cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Uveal melanoma
Focus Adverse reactions; First in man; Pharmacodynamics; Proof of concept; Therapeutic Use
Sponsors Rubius Therapeutics [CEASED]

09 Dec 2022 Status changed from active, no longer recruiting to discontinued.
26 Sep 2022 Status changed from discontinued to active, no longer recruiting.
13 Sep 2022 Status changed from recruiting to discontinued, according to a Rubius Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com